Insider trade

Director sold ~$580K of RGEN shares in the open market

Traded Nov 12, 2025 · Filed Nov 14, 2025

Why it stands out

A Repligen director sold $580K of Repligen shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$579,556

Shares × reported transaction price

Timing vs results

15 days after results of Oct 28, 2025, 104 days before results of Feb 24, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+6.7%	−1.9%	+8.6%
30 days	+5.4%	+1.3%	+4.1%
90 days	−13.0%	+1.4%	−14.3%
180 days	−29.8%	+10.5%	−40.2%

Past results only. Not a forecast.

Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024.
$154.92 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.26 to $155.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.